The HIV-1 transgenic rat model of neuroHIV.
Despite the ability of current combination anti-retroviral therapy (cART) to limit the progression of HIV-1 to AIDS, HIV-positive individuals continue to experience neuroHIV in the form of HIV-associated neurological disorders (HAND), which can range from subtle to substantial neurocognitive impairment. NeuroHIV may also influence substance use, abuse, and dependence in HIV-positive individuals. Because of the nature of the virus, variables such as mental health co-morbidities make it difficult to study the interaction between HIV and substance abuse in human populations. Several rodent models have been developed in an attempt to study the transmission and pathogenesis of the HIV-1 virus. The HIV-1 transgenic (HIV-1Tg) rat is a reliable model of neuroHIV because it mimics the condition of HIV-infected patients on cART. Research using this model supports the hypothesis that the presence of HIV-1 viral proteins in the central nervous system increases the sensitivity and susceptibility of HIV-positive individuals to substance abuse.
Institute of NeuroImmune Pharmacology and Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA.
Michael
M
Vigorito
Institute of NeuroImmune Pharmacology and Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA.
Kaitlyn P
KP
Connaghan
Institute of NeuroImmune Pharmacology and Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA. Electronic address: sulie.chang@shu.edu.
Sulie L
SL
Chang
D015526:AIDS Dementia Complex / Q000523:psychology*; D000818:Animals; D004195:Disease Models, Animal; D015658:HIV Infections / Q000523:psychology*; D015497:HIV-1; D051379:Mice; D051381:Rats; D055647:Rats, Transgenic
HIV-1 transgenic rat; NeuroHIV; Substance abuse